P01.129 Cost-effectiveness of [18F] FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting

Por Baguet, T, Verhoeven, J, de Vos, F, Goethals, I
Publicado no Neuro Oncol (2018)

Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy

Por de Vos, F.Y.F.L., de Wit, R.
Publicado em 2010

Synthesis, radiosynthesis and in vivo evaluation of [(123)I]-4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine as a selective tracer for imaging the dopamine trans...

Por De Bruyne, S., Boos, T. L., wyffels, L., Goeman, J. L., Rice, K. C., De Vos, F.
Publicado em 2009

P16.04 USE OF 18F-FLUOROMETHYLCHOLINE PET IN EARLY TREATMENT RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS

Por Bolcaen, J., Acou, M., Boterberg, T., Deblaere, K., De Vos, F., Hallaert, G., Kalala, J., Van den Broecke, C.
Publicado em 2014

P07.22 Kinetic modeling and graphical analysis of 18F-fluoromethylcholine (FCho), 18F-fluoroethyltyrosine (FET) and 18F-fluorodeoxyglucose (FDG) PET for the discrimination between...

Por Bolcaen, J., Lybaert, K., Moerman, L., Descamps, B., Deblaere, K., Boterberg, T., Kalala, J., De Vos, F., Vanhove, C., Goethals, I.
Publicado no Neuro Oncol (2016)

P04.82 [(18)F]-FET and [(18)F]-FAZA PET based radiotherapy of F98 glioblastoma rats

Por Verhoeven, J, Bolcaen, J, Donche, S, de Meulenaere, V, Descamps, B, Hallaert, G, Kersemans, K, Boterberg, T, Vanhove, C, de Vos, F, Goethals, I
Publicado no Neuro Oncol (2018)

P04.26 In vitro and in vivo evaluation of the LAT1 PET tracer 2-[(18)F]FELP in comparison to [(18)F]FET and [(18)F]FDG

Por Verhoeven, J., Bolcaen, J., Kersemans, K., De Meulenaere, V., Deblaere, K., Kalala, J., Van den Broecke, C., Vanhove, C., Goethals, I., De Vos, F.
Publicado no Neuro Oncol (2017)

A randomized controlled trial of a skills training for oncologists and a communication aid for patients to stimulate shared decision making about palliative systemic treatment (CHO...

Por Henselmans, I., Smets, E. M. A., de Haes, J. C. J. M., Dijkgraaf, M. G. W., de Vos, F. Y., van Laarhoven, H. W. M.
Publicado no BMC Cancer (2018)

RARE-12 TOXICITY AND RESPONSE IN PATIENTS TREATED ACCORDING TO THE DUTCH SOCIETY FOR NEURO-ONCOLOGY (LWNO) MEDULLOBLASTOMA TREATMENT PROTOCOL WITH NEOADJUVANT CHEMOTHERAPY, RADIATI...

Por Gravendeel, L.A., van der Rijt, C.C.D., Seute, D.T., de Vos, F.Y.F., van Linde, M.E., Eekers, D.B., Botterweck, A.A., Boogerd, W., Bromberg, J.E.C.
Publicado no Neuro Oncol (2015)

P01.037 Quality criteria for glioma care, use in clinical practice: results of a national survey

Por de Peuter, M A, van Baest, L, Bienfait, H P, Dujardin, K, Hanse, M C J, Vos, M J, de Vos, F Y F L, Ho, V K Y, Gijtenbeek, J M M
Publicado no Neuro Oncol (2018)

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomusti...

Por Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, H M, Walenkamp, A M, Beerepoot, L, Hanse, M, van Linde, M E, Otten, A, Vernhout, R M, de Vos, F Y F, Gratama, J W, Sleijfer, S, van den Bent, M J
Publicado no Br J Cancer (2015)